Detailed Narrative
Dupixent's Broad Impact and Growth Trajectory
Dupixent continues to demonstrate strong global growth, with worldwide net sales reaching $4.9 billion (up 26% constant currency) and U.S. net sales at $3.6 billion (up 28% YoY). It maintains market leadership across established indications and is approved for 8 distinct type 2 inflammatory diseases in the U.S., treating over 1.3 million patients globally. The drug's approved indications could address over 4 million U.S. patients, positioning it as a significant long-term growth driver.
EYLEA HD Regulatory Challenges and Commercial Strategy
EYLEA HD achieved record U.S. net sales of $431 million, driven by robust physician demand despite competitive pricing. However, its prefilled syringe sBLA received a Complete Response Letter due to unresolved inspection findings at a Catalent facility. Regeneron is pursuing an alternate prefilled syringe filler submission by January 2026 and an alternate vial filler with a PDUFA date in late December to address these issues and unlock full commercial potential through label enhancements like 4-week dosing and RVO indication.
Libtayo's Expanding Oncology Footprint
Libtayo global net sales grew 24% constant currency to $365 million, with U.S. sales up 12% to $219 million. It maintains market leadership in non-melanoma skin cancers and is gaining share in lung cancer. The recent FDA approval for adjuvant cutaneous squamous cell carcinoma (CSCC) makes it the first and only PD-1 antibody for this setting, with an estimated 10,000 addressable patients in the U.S., marking a strong early launch.
Aggressive Pipeline Advancement and Strategic Investments
Regeneron reported positive Phase III or registration-enabling data for 6 distinct programs in immunology, neurology, allergy, and rare diseases. The company plans to rapidly expand pivotal programs in hematology/oncology, thrombosis, obesity, metabolic diseases, and allergies. Significant R&D investments are ongoing, with a projected mid-teens percentage increase in R&D expense for 2026 to support these efforts.
Commitment to Domestic Manufacturing and Drug Cost Discussions
Regeneron is engaged in constructive discussions with the U.S. government to lower drug costs while preserving innovation and strengthening domestic manufacturing. The company has committed over $7 billion to infrastructure and manufacturing facilities in New York and North Carolina, aligning with the administration's goals to ensure equitable global burden-sharing for drug development and safeguard national security.
Lynozyfic's Potential in Multiple Myeloma
Lynozyfic, a BCMAxCD3 bispecific, has been approved for relapsed/refractory multiple myeloma in the U.S. and EU, showing potential for best-in-class efficacy in late-line settings. Promising Phase II results in high-risk smoldering myeloma (100% ORR) and newly diagnosed patients (83% ORR) support a planned Phase III head-to-head study against Darzalex and aggressive pursuit of earlier treatment lines.
Cemdisiran's Best-in-Class Potential for gMG
The C5 siRNA cemdisiran demonstrated statistically significant Phase III results for generalized myasthenia gravis (gMG) with convenient subcutaneous quarterly dosing. Its efficacy, safety, and convenience profile position it as a potential best-in-class treatment option, with a U.S. regulatory application planned for Q1 2026.